Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral deucrictibant extended-release tablets for prophylaxis of hereditary angioedema attacks
CTR20253897Phase 3Completed
- Sponsor
- Pharvaris
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Jan 2026; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20253897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253897.